Blog | Genomic Testing Cooperative

HALO Diagnostics and Genomic Testing Cooperative Partner to Advance Early Cancer Detection and Precision Diagnostics

SAN FRANCISCO (PRWEB) JUNE 14, 2022. HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.

ASCO 2022 GTC Posters

vexas disease- Bone Marrow Aspirate NEJM

Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia or multiple myeloma, but characterized […]

Genomic Testing Cooperative to Reveal “Liquid Trace™” at ASCO, a Liquid Biopsy Test that Combines Cell-Free DNA with Targeted Transcriptome and to Present Data on its Advanced AI for the Diagnosis of Hematologic and Solid Tumors

Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™. Liquid Trace tests both cfDNA and […]

IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as well as its liquid biopsy profiles for both solid tumors and hematology that are designed to provide a wide range of clinically actionable insights about a patient’s tumor. The CE […]

What are some of the hematologic manifestations of VEXAS syndrome?

A Man with a Recurrent Left Pleural Effusion In late 2020, a new disease entity that was referred to as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was reported. Q: What is the cause of VEXAS syndrome?A: VEXAS syndrome is caused by somatic mutations in UBA1 (the gene that encodes ubiquitin-like modifier activating enzyme 1), which initiates […]

Genomic Testing Cooperative and their Cooperative Member Laboratories Expand Hematology Panels to Cover VEXAS Disease and a New Prognostic Biomarker in Myeloproliferative Neoplasms

IRVINE, California, March 2, 2022, Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1 and NFE2 genes. Both genes were recently reported to be clinically important for the diagnosis and treatment of patients with hematologic neoplasms. Recently described VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, […]

Abstract Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learning, we developed an approach to stratify patients with DLBCL into four subgroups based on survival characteristics. This approach uses data from the targeted transcriptome to predict […]

Posters at ASH21 In partnership with Anthology Diagnostics and Key Genomics, GTC presented four abstracts at ASH 2021 GTC’s posters from 2021 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions. Download Poster Download Poster Download Poster Download Poster Read more Articles and News from GTC

Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA Transcriptome Data and on the Use of Liquid Biopsy

Irvine, California– December 1, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH) meeting new data on the use of their proprietary machine learning approaches in the diagnosis of acute graft-versus-host disease (aGVHD) and for the stratifying of patients with diffuse large B-cell […]

Innovation in Next Generation Sequencing

Making Genomics Available and Affordable for Everyone

HALO Diagnostics and Genomic Testing Cooperative Partner to Advance Early Cancer Detection and Precision Diagnostics

ASCO 2022 Posters

Case Study: VEXAS Syndrome

Genomic Testing Cooperative to Reveal “Liquid Trace™” at ASCO, a Liquid Biopsy Test that Combines Cell-Free DNA with Targeted Transcriptome and to Present Data on its Advanced AI for the Diagnosis of Hematologic and Solid Tumors

Genomic Testing Cooperative Hematology Profile Plus, Solid Tumor Profile Plus, and Liquid Biopsy Profiles Receive CE-IVD Mark

What are some of the hematologic manifestations of VEXAS syndrome?

Genomic Testing Cooperative and their Cooperative Member Laboratories Expand Hematology Panels to Cover VEXAS Disease and a New Prognostic Biomarker in Myeloproliferative Neoplasms

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

ASH21 Posters

Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA Transcriptome Data and on the Use of Liquid Biopsy